Regenerate. Repair. Restore.

Stem Cells Therapy for COPD And Inflammatory Lung Disease

Chronic Obstructive Pulmonary Disease (COPD), is a medical term used to describe a group of chronic, inflammatory lung diseases including emphysema, chronic bronchitis, refractory asthma and bronchiectasis. 

Stem cell transplantation is a promising treatment option for COPD and other inflammatory lung diseases.

The Stem Cells Transplant Institute’s stem cell treatment could help with COPD signs and symptoms like:

  • Shortness of breath, especially during physical activities
  • Wheezing
  • Chest tightness
  • Excess mucus in your lungs
  • Chronic cough Frequent respiratory infections
  • Lack of energy
  • Swelling in ankles, feet or legs
  • Cyanosis or blueness of the lips and fingernails

What do we know about COPD?

Chronic obstructive pulmonary disease is the world’s fourth leading cause of death.1 Long-term exposure to substances that irritate and damage the lungs is the main cause of COPD.

Long-term cigarette smoking is the most significant risk factor for developing COPD, but other risks include second hand smoke exposure, chemical fumes, dust, age and genetics.

Emphysema and bronchitis are the two most common types of COPD. Air travels down your windpipe into your lungs through tubes (bronchi). These tubes divide into smaller tubes, including air sacs (alveoli) at the ends of these smaller tubes (bronchioles).

Bronchitis causes inflammation and narrowing of the bronchial tubes, causing mucus to build up, while emphysema slowly destroys the air sacs, interfering with the outward flow of air.

Your lungs rely on the natural elasticity of the bronchial tubes and air sacs to force air out of your body. COPD causes them to lose their elasticity, leaving some air trapped in your lungs as you exhale.

Current treatment options provide symptomatic relief but are not curative. Conventional therapies include a combination of pharmaceutical drugs, lifestyle changes, oxygen, and as a last resort, surgery.

Can stem cell therapy improve the signs and symptoms of COPD?

Chronic pulmonary and systemic inflammation are hallmarks of COPD. Mesenchymal stem cells improve lung function by modulating the immune system and reducing inflammation.

Pre-clinical studies of stem cell therapy reveal that mesenchymal stem cells can regenerate alveolar-like structures, repair emphysematous lungs, and reduce inflammatory responses.

Mesenchymal stem cells are believed to improve lung function by signaling a patient’s cells to secrete molecules such as peptides, extracellular matrix proteins, and growth factors that can help repair and regenerate tissue.

A meta-analysis of 36 different clinical trials found mesenchymal stem cells treatment to be safe with no significant adverse events or malignant transformations.6

In phase 1 trials, the inflammatory marker C-reactive protein (CRP) was reduced and another phase 1 trial showed treatment with MSCs increased the expression of CD31, the endothelial cell marker in found in the alveolar septa of emphysematous lung tissue5. These findings suggest that MSCs can reduce inflammation and improve angiogenesis to aid in the repair of damaged lung tissue COPD patients.

There are currently 23 clinical trials evaluating the safety and/or efficacy of stem cell treatment for COPD and inflammatory lung disease, according to (

Stem cell treatment with mesenchymal stem cells in conjunction with lifestyle modification can improve the symptoms of COPD. Stem cell treatment increases your respiratory capacity and your breathing improves over time.

What are the advantages of human umbilical cord mesenchymal stem cells?

  • Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
  • hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
  • Greater proliferation ability than adult autologous stem cells
  • They regenerate at a very rapid rate They are young and very adaptive
  • They have not been impacted by the aging process
  • They have not been affected by environmental toxins
  • Umbilical cord stem cells can be administered multiple times over the course of days

Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time

What is the recommended treatment protocol for COPD and inflammatory lung disease at the Stem Cells Transplant Institute?

  • Mesenchymal stem cells derived from human umbilical cord tissue.
  • Antioxidant therapy with vitamin C and glutathione.
  • Ozone therapy.
  • Platelet-rich plasma therapy (PRP).
umbilical cord donations
Intravenus Administration

How Are the Stem Cells Collected?

Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.

How Are the Stem Cells Administered?

Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.

About the Stem Cells Transplant Institute

Our clinic is located in Costa Rica, which is one of the most popular medical tourism destinations for stem cell therapy. At the Stem Cells Transplant Institute, we have a skilled team of doctors and medical professionals who collect and administer stem cells to treat autism and other conditions. Every patient receives the most cost-effective and top-notch care from our dedicated team.

Scientific References:

  1. Cheng et al. Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science Stem Cells International. Volume 2017, Article ID 8916570. 14pages.
  2. Weiss et al. A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD. CHEST 2013; 143(6):1590–1598
  3. Antoniou, K.M., Karagiannis, K., Tsitoura, E., Bibaki, E., Lasithiotaki, I., Proklou, A. … Tzanakis, N. (2018). Clinical applications of mesenchymal stem cells in chronic lung diseases (Review). Biomedical Reports, 8, 314-318.
  4. Weiss, D.J.; Casaburi, R.; Flannery, R.; LeRoux-Williams, M.; Tashkin, D.P. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest2013143, 1590–1598.
  5. Stolk, J.; Broekman, W.; Mauad, T.; Zwaginga, J.J.; Roelofs, H.; Fibbe, W.E.; Oostendorp, J.; Bajema, I.; Versteegh, M.I.; Taube, C.; et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM2016
  6. Lalu, M.M.; McIntyre, L.; Pugliese, C.; Fergusson, D.; Winston, B.W.; Marshall, J.C.; Granton, J.; Stewart, D.J.; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS ONE20127, e47559.